VisualDx vs Maudsley Deprescribing Guide

VisualDx is a visual reference tool for medical professionals that leverages AI technology and a comprehensive image atlas to support faster, more confident decisions, fewer unnecessary referrals and testing, and higher patient engagement and satisfaction. With VisualDx, clinicians can: • Build dynamic differentials that evolve as you think. • Use guided support to surface clinically relevant results. • Compare diagnoses to improve decisions for your patients. • Use our AI to take a picture of your patient’s skin condition to better understand morphology and possibilities. • Engage with patients by sharing pictures of skin that reflect their disease presentation. • Access therapy and testing recommendations across over 3,500 conditions. • Quickly recognize infectious diseases and travel-related illnesses with our public health resources. • Test your diagnostic skills with our image challenges and educational resources. • Earn 0.5 AMA PRA Category 1 Credits™ for internet point of care activity with every search. See why this award-winning clinical decision support system is being used in more than 2,300 hospitals, clinics, and medical schools by physicians, nurses, students, PAs, NPs, and other healthcare professionals worldwide. VisualDx requires a subscription. Terms of Use: https://www.visualdx.com/legal/acceptable-use-policy-notice Privacy Policy: https://www.visualdx.com/legal/privacy-policy/

"Try before you buy"-Download the FREE App,which includes sample content. In-App purchase required to unlock all content. The Maudsley Deprescribing Guidelines provide evidence-based recommendations for safely discontinuing antidepressants, benzodiazepines, gabapentinoids, and Z-drugs. This resource is essential for healthcare professionals aiming to optimize patient care and minimize medication-related harm. It emphasizes a patient-centered approach, ensuring that deprescribing is conducted thoughtfully and effectively. Most formal guidance on psychiatric medication relates to starting or switching medications with minimal guidance on deprescribing medication. In 2023, the World Health Organisation and the United Nations called for patients, as a human right, to be informed of their right to discontinue treatment and to receive support to do so. The Maudsley Deprescribing Guidelines fills a significant gap in guidance for clinicians by providing comprehensive and authoritative information on this important aspect of treatment. This evidence-based handbook provides an overview of principles to be used in deprescribing. This is derived from fundamental scientific principles and the latest research on this topic, combined with emerging insights from clinical practice (including from patient experts). Building on the recognised brand of The Maudsley Prescribing Guidelines, and the prominence of the authors’ work, including in The Lancet Psychiatry on tapering antidepressants (the most read article across all Lancet titles when it was released). The Maudsley Deprescribing Guidelines covers topics such as: - Why and when to deprescribe antidepressants, benzodiazepines, gabapentinoids and z-drugs - Barriers and enablers to deprescribing including physical dependence, social circumstances, and knowledge about the discontinuation process - Distinguishing withdrawal symptoms, such as poor mood, anxiety, insomnia, and a variety of physical symptoms from symptoms of the underlying disorder that medication was intended to treat - The difference between physical dependence and addiction/substance use disorder - Explanation of why and how to implement hyperbolic tapering in clinical practice - Specific guidance on formulations of medication and techniques for making gradual reductions, including using liquid forms of medication, and other approaches - Step-by-step guidance for safely stopping all commonly used antidepressants, benzodiazepines, gabapentinoids and z-drugs, including fast, moderate and slow tapering regimens or schedules for each drug, and guidance on how to tailor these to an individual - Troubleshooting issues which can arise on stopping these medications, including akathisia, withdrawal symptoms, acute or protracted, and relapse. - Written for anyone interested in safe deprescribing of psychiatric medications including psychiatrists, GPs, pharmacists, nurses, medical trainees, and interested members of the public. The Maudsley Deprescribing Guidelines is an essential resource on the subject that provides practical guidance on how to improve patient outcomes in this field of medicine. Disclaimer : App developers do not endorse or recommend any specific medications. Always consult a qualified healthcare provider before starting, changing, or stopping any medication. Content licensed from printed ISBN 10: 1119823021 Content licensed from printed ISBN 13: 9781119823025 If you have any questions or comments,email us any time:customersupport@skyscape.com or call 508-299-3000 Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspx Terms & Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx Author:Deanna Mark Horowitz; David M. Taylor Publisher:Wiley-Blackwell